ciprofibrate has been researched along with Cardiometabolic Syndrome in 2 studies
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Paragh, G | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Erdei, A | 1 |
| Audikovszky, M | 1 |
| Debreczeni, L | 1 |
| Kovácsay, A | 1 |
| Illyés, L | 1 |
| Pados, G | 1 |
2 other studies available for ciprofibrate and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
Topics: Aryldialkylphosphatase; Case-Control Studies; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans | 2006 |